The acquisition enhances the Clario Respiratory Solutions portfolio, combining Clario’s deep scientific expertise with ArtiQ’s innovative artificial intelligence capabilities
- Clario respiratory devices will seamlessly integrate with ArtiQ’s AI models to provide instant feedback on test quality, delivering faster, more reliable data for sponsors and providing a better patient experience.
- The addition of ArtiQ, along with Clario’s recent acquisition of Inofab Health, expands Clario a leading position in respiratory clinical trial support and expands existing AI capabilities that include more than 50 proprietary AI/ML algorithms.
- CEO of ArtiQ Marko Topalovic will join Clari and continue to lead ArtiQ doc at the same time leading the company’s AI.
PHILADELPHIA, April 2, 2024 /PRNewswire/ — Clario, a healthcare research and technology company that delivers leading endpoint technology solutions for clinical trials, today announced the acquisition of technology company ArtiQ. This acquisition expands the artificial intelligence (AI) power of the Clario Respiratory Solutions portfolio and enhances the company’s ability to further leverage and develop the innovative use of AI in its service lines.
“We are thrilled to welcome ArtiQ to our organization,” he said Chris Fikrychief executive officer of Clario. “Since 2018, Clario has been a pioneer in the application of artificial intelligence to improve the quality and efficiency of clinical trial execution. This move significantly advances AI within our respiratory portfolio. With ArtiQ’s technology, we expand our ability to rapidly scale AI for throughput while ensuring data quality and streamlining processes clinical trials for patients around the world.”
In addition to continuing to lead ArtiQ, Marko Topalovic will step into leadership of Clario’s overall AI strategy across the organization. He said of the acquisition: “Joining forces with Clario is a pivotal moment for ArtiQ. Integrating our technology into Clario’s portfolio not only improves the quality and efficiency of spirometry data analysis, but also marks a significant step towards reducing patient burden and improving trial outcomes. At Clario, our technology can be extended worldwide to all clinical trials and sponsors, and we now have the opportunity to drive positive impact beyond the scope of respiratory care.”
In addition to the ArtiQ acquisition, Clario acquired Inofab Health, a maker of easy-to-use ultrasound sensor spirometers. November 2023. Combining these acquisitions with Clario’s deep breathing scientific capabilities will strengthen the Clario Respiratory Solutions portfolio, serve as a starting point for advancing AI within clinical trials, and increase its reach in the broader healthcare market.
“We are committed to pioneering artificial intelligence models that help rapidly deliver high-quality data in clinical trials,” he said. Jay FerroClario’s Chief Information, Technology and Product Officer. “This acquisition reinforces that commitment and ensures that we continue to fulfill our mission of helping our customers transform the lives of patients around the world.”
To learn more about the Clario Respiratory Solutions portfolio and scientific expertise, visit Clario.com.
Latham & Watkins advised Clario on the transaction.
About Clario
Clario is a leading healthcare research and technology company that generates the highest quality clinical evidence for our pharmaceutical, biotechnology and medical device partners. We offer end-to-end evidence generation solutions that combine eCOA, cardiac safety, medical imaging, precision motion and respiratory endpoints.
Clario’s global team of scientific, technological and operational experts has helped conduct more than 26,000 trials and contributed to more than 800 regulatory approvals in more than 100 countries. For more than 50 years, we have provided deep scientific expertise and the broadest endpoint technologies to help transform lives around the world.
For more information, go to Clario.com or follow us on LinkedIn.
About ArtiQ
ArtiQ, a spin-off from the Belgian university KU Leuven, is a leading innovative software company dedicated to improving the diagnosis and monitoring of patients with respiratory conditions. Moreover, ArtiQ aims to simplify and optimize respiratory clinical trials for pharmaceutical companies. By developing and delivering cutting-edge AI-first software, ArtiQ empowers traditional respiratory devices and processes.
ArtiQ was launched in 2019 with the support of KU Leuven, University Hospital Leuven and early investors Gemma Frisius Fund and KBC Focus Fund. Since then, together with researchers, clinicians, equipment manufacturers and pharmaceutical companies, we have been on a mission to make crucial improvements for patients with lung disease.
You can find more information at www.artiq.eu or follow us on LinkedIn and Twitter.
Contact for Clario media:
Alexis Navratil
Head of Communications
[email protected]
SOURCE Clario
